CO2020003061A2 - Inhibidores de cxcr-2 para tratar trastornos - Google Patents
Inhibidores de cxcr-2 para tratar trastornosInfo
- Publication number
- CO2020003061A2 CO2020003061A2 CONC2020/0003061A CO2020003061A CO2020003061A2 CO 2020003061 A2 CO2020003061 A2 CO 2020003061A2 CO 2020003061 A CO2020003061 A CO 2020003061A CO 2020003061 A2 CO2020003061 A2 CO 2020003061A2
- Authority
- CO
- Colombia
- Prior art keywords
- activity
- cxcr
- inhibitors
- treat disorders
- diseases
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 2
- 102000003896 Myeloperoxidases Human genes 0.000 abstract 2
- 108090000235 Myeloperoxidases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000000589 Interleukin-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229960001338 colchicine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- UCCNQCNIPRKLRP-CJNGLKHVSA-N n-[6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide Chemical compound N=1C(SCC=2C=CC(F)=CC=2)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CC(C)C1 UCCNQCNIPRKLRP-CJNGLKHVSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/702,693 US20180221312A1 (en) | 2016-03-11 | 2017-09-12 | Cxcr-2 inhibitors for treating disorders |
| PCT/US2018/050656 WO2019055509A1 (fr) | 2017-09-12 | 2018-09-12 | Inhibiteurs de cxcr-2 pour le traitement de troubles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020003061A2 true CO2020003061A2 (es) | 2020-06-19 |
Family
ID=65723077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0003061A CO2020003061A2 (es) | 2017-09-12 | 2020-03-16 | Inhibidores de cxcr-2 para tratar trastornos |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3681861A4 (fr) |
| JP (1) | JP2020533332A (fr) |
| CN (1) | CN111356675A (fr) |
| AR (1) | AR112801A1 (fr) |
| AU (1) | AU2018334152A1 (fr) |
| BR (1) | BR112020004697A2 (fr) |
| CA (1) | CA3075305A1 (fr) |
| CO (1) | CO2020003061A2 (fr) |
| MX (2) | MX2020002754A (fr) |
| TW (1) | TW201919599A (fr) |
| WO (1) | WO2019055509A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10772886B2 (en) | 2016-03-11 | 2020-09-15 | Ardea Biosciences, Inc. | CXCR-2 inhibitors for treating crystal arthropathy disorders |
| US20220404373A1 (en) * | 2019-09-25 | 2022-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and treating uveitis |
| WO2021089715A1 (fr) * | 2019-11-06 | 2021-05-14 | Murray And Poole Enterprises, Ltd. | Utilisation de colchicine dans le traitement et la prévention du cancer du poumon |
| MX2022005795A (es) * | 2019-11-13 | 2022-06-08 | Rapt Therapeutics Inc | Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas. |
| EP4161499A1 (fr) * | 2020-06-05 | 2023-04-12 | Aristea Therapeutics, Inc. | Utilisation d'une combinaison de colchicine et d'un inhibiteur cxcr-2 pour le traitement ou la prévention de la fièvre méditerranéenne familiale (fmf) et ses poussées |
| TWI774059B (zh) * | 2020-09-14 | 2022-08-11 | 國立陽明大學 | Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途 |
| TW202227081A (zh) * | 2020-09-15 | 2022-07-16 | 美商雅力思提雅治療公司 | 用於治療掌蹠膿疱症之組合物及方法 |
| US20240026295A1 (en) * | 2020-09-24 | 2024-01-25 | Edigene (Guangzhou) Inc. | Use of compound for improving transplantation efficiency of human hematopoietic stem cells |
| CN115385865B (zh) * | 2022-06-29 | 2023-06-16 | 深圳大学 | 一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用 |
| CN117503740A (zh) * | 2023-11-09 | 2024-02-06 | 复旦大学 | 一种bach1抑制剂及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06008599A (es) * | 2004-01-30 | 2006-08-28 | Schering Corp | Polimorfos cristalinos de un ligando receptor de cxc-quimiocina. |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| EP2731945A1 (fr) * | 2011-07-12 | 2014-05-21 | AstraZeneca AB | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio) pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide utilisé en tant que modulateur du récepteur de chimiokine |
| US10772886B2 (en) * | 2016-03-11 | 2020-09-15 | Ardea Biosciences, Inc. | CXCR-2 inhibitors for treating crystal arthropathy disorders |
-
2018
- 2018-09-12 CA CA3075305A patent/CA3075305A1/fr active Pending
- 2018-09-12 AR ARP180102592A patent/AR112801A1/es unknown
- 2018-09-12 BR BR112020004697-3A patent/BR112020004697A2/pt not_active IP Right Cessation
- 2018-09-12 CN CN201880073230.7A patent/CN111356675A/zh active Pending
- 2018-09-12 EP EP18856459.5A patent/EP3681861A4/fr not_active Withdrawn
- 2018-09-12 TW TW107132083A patent/TW201919599A/zh unknown
- 2018-09-12 JP JP2020514219A patent/JP2020533332A/ja active Pending
- 2018-09-12 MX MX2020002754A patent/MX2020002754A/es unknown
- 2018-09-12 AU AU2018334152A patent/AU2018334152A1/en not_active Abandoned
- 2018-09-12 WO PCT/US2018/050656 patent/WO2019055509A1/fr active Application Filing
-
2020
- 2020-03-11 MX MX2022014868A patent/MX2022014868A/es unknown
- 2020-03-16 CO CONC2020/0003061A patent/CO2020003061A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201919599A (zh) | 2019-06-01 |
| AU2018334152A1 (en) | 2020-04-23 |
| EP3681861A1 (fr) | 2020-07-22 |
| BR112020004697A2 (pt) | 2020-10-27 |
| MX2020002754A (es) | 2020-07-20 |
| WO2019055509A1 (fr) | 2019-03-21 |
| AR112801A1 (es) | 2019-12-11 |
| JP2020533332A (ja) | 2020-11-19 |
| EP3681861A4 (fr) | 2021-06-09 |
| CN111356675A (zh) | 2020-06-30 |
| MX2022014868A (es) | 2022-12-15 |
| CA3075305A1 (fr) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020003061A2 (es) | Inhibidores de cxcr-2 para tratar trastornos | |
| CO2018010880A2 (es) | Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| CL2019000979A1 (es) | Composiciones y anticuerpos anti-lag-3. | |
| CL2021001321A1 (es) | Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta | |
| DOP2020000252A (es) | Inhibidores de proteina tirosina fosfatasa y sus métodos de uso | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| PA8570701A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos para su preparacion | |
| CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
| CO2022009438A2 (es) | Fluoroalquil-oxadiazoles y sus usos | |
| UY38999A (es) | Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos | |
| ECSP12012171A (es) | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos | |
| BR112022007677A2 (pt) | L-asparaginase recombinante | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| PE20220562A1 (es) | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida | |
| CL2021001537A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| ECSP19026702A (es) | Compuestos novedosos para el tratamiento de enfermedades parasitarias | |
| DOP2013000308A (es) | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
| CL2012001671A1 (es) | Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras. | |
| CO2023010940A2 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder |